- Investing Ideas
- /
- Global High Growth Potential Companies
Global High Growth Potential Companies
Results
8544
0 new
Companies with a Future performance score of at least 3, ordered by Future performance score.
8,544 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
ZVRA | US$7.79 | 12.2% | 68.6% | US$378.8m | US$20.43 | PS17.3x | E69.7% | n/a | Pharmaceuticals & Biotech | ||
TGTX | US$21.31 | -8.9% | 197.6% | US$3.2b | US$33.75 | PE31.9x | E43.5% | n/a | Pharmaceuticals & Biotech | ||
KEBNI B | SEK 1.14 | -7.2% | -8.4% | SEK 308.0m | SEK 2.20 | PS2.7x | E86.1% | n/a | Tech | ||
MBTN | CHF 1.55 | -3.7% | -99.2% | CHF 47.8m | CHF 6.03 | PB0.2x | E95.4% | n/a | Semiconductors | ||
MVW | NOK 10.40 | 1.0% | 35.8% | NOK 340.3m | NOK 12.20 | PS19.8x | E70.8% | n/a | Materials | ||
RHM | €506.20 | 4.1% | 102.1% | €22.0b | €616.44 | PE33.7x | E27.7% | 1.1% | Capital Goods | ||
ARES | US$160.56 | 3.0% | 47.0% | US$50.2b | US$154.15 | PE84.8x | E32.9% | 2.3% | Diversified Financials | ||
AESI | US$22.62 | 3.8% | 5.3% | US$2.5b | US$25.91 | PE17x | E42.1% | 4.1% | Energy | ||
AXSM | US$84.16 | -6.4% | 19.6% | US$4.2b | US$125.29 | PS13.9x | E68.9% | n/a | Pharmaceuticals & Biotech | ||
TVTX | US$15.26 | 9.1% | 114.3% | US$1.2b | US$17.00 | PS6.6x | E69.3% | n/a | Pharmaceuticals & Biotech | ||
SCOL | SEK 0.14 | -6.1% | -91.3% | SEK 32.0m | n/a | PB0.7x | E75.3% | n/a | Pharmaceuticals & Biotech | ||
NEWBRY | SEK 3.86 | 2.1% | 21.8% | SEK 93.6m | SEK 8.00 | PS5.1x | E116.2% | n/a | Pharmaceuticals & Biotech | ||
NVG | zł1.79 | -3.2% | -23.5% | zł62.7m | zł3.65 | PE231.3x | E41.4% | 3.4% | Diversified Financials | ||
CADLR | NOK 75.70 | 2.3% | 114.4% | NOK 26.6b | NOK 81.94 | PS18.5x | E67.8% | n/a | Capital Goods | ||
ICOP | €7.16 | 9.5% | n/a | €197.9m | €9.30 | PE39.2x | E49.2% | n/a | Capital Goods | ||
LAVV3 | R$8.12 | 0.6% | 11.7% | R$1.6b | R$12.98 | PE5.8x | E21.1% | 3.5% | Real Estate Management and Development | ||
CALTX | SEK 205.80 | -0.5% | 108.5% | SEK 11.1b | SEK 227.50 | PS6.9x | E50.4% | n/a | Pharmaceuticals & Biotech | ||
RMDA | ج.م3.26 | 4.8% | 143.1% | ج.م4.9b | ج.م4.11 | PE21.6x | E30.2% | 2.1% | Pharmaceuticals & Biotech | ||
EH | US$21.27 | 50.4% | 24.4% | US$1.1b | US$24.35 | PS37.9x | E81.4% | n/a | Capital Goods | ||
3DA | AU$0.39 | -10.5% | 32.8% | AU$233.8m | n/a | PS497.7x | E59.4% | n/a | Capital Goods | ||
SRPT | US$117.79 | -5.7% | -4.6% | US$11.5b | US$194.41 | PE237.5x | E44.1% | n/a | Pharmaceuticals & Biotech | ||
NVDA | US$127.72 | 9.2% | 178.9% | US$3.1t | US$149.86 | PE59.1x | E22.4% | 0.03% | Semiconductors | ||
SKS | AU$1.45 | -3.3% | 643.6% | AU$162.5m | AU$1.80 | PE24.5x | E24.8% | 0.7% | Capital Goods | ||
CUV | AU$13.96 | -3.9% | -9.9% | AU$707.7m | AU$29.17 | PE19.6x | E27.4% | 0.4% | Pharmaceuticals & Biotech |